Document is current
Any future updates will be listed below
-
Authors
Zhao, Fangyuan
Polley, Eric
McClellan, Julian
Howard, Frederick
Olopade, Olufunmilayo I.
Huo, Dezheng
-
Funding
Funding for this research was provided by:
Susan G. Komen (TREND21675016)
Breast Cancer Research Foundation (BCRF-23-071, BCRF-23-071)
National Cancer Institute (P20CA233307, P20CA233307)
U.S. Department of Defense (W81XWH2210791, W81XWH2210791)
- License Information
-
More Information
Article History
Received: 20 May 2024
Accepted: 16 October 2024
First Online: 29 October 2024
Declarations
:
: The Institutional Review Board at the University of Chicago granted a waiver status for the use of NCDB data in this study because no protected health information was reviewed, and the analysis was retrospective using de-identified data. The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigators. The study protocol in ChiMEC was approved by the Institutional Review Board at the University of Chicago, and all participants provided their written informed consent.
: Not applicable.
: OIO has disclosed financial relationships with CancerIQ, HealthWell Solutions, Tempus; research funding from Ayala Pharmaceuticals, Cepheid, Color Genomics, Novartis, and Roche/Genentech. The other authors, FZ, EP, JM, FH, and DH, declare no financial or non-financial competing interests.
